- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00006360
Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer
Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy in treating patients who have stage II or stage III oropharyngeal cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES:
- Assess target coverage and major salivary gland sparing in patients with stage II or III oropharyngeal cancer treated with intensity-modulated radiotherapy.
- Determine the nature and prevalence of acute and late side effects of this treatment in these patients.
- Determine the rate and pattern of locoregional tumor recurrence in these patients after this treatment.
OUTLINE: This is a multicenter study.
Patients receive 3-D conformal radiotherapy and/or intensity-modulated radiotherapy daily 5 days a week for 6 weeks, in an effort to spare major salivary glands.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 57-64 patients will be accrued for this study over 27 months.
Studietype
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2R7
- Stollery Children's Hospital at University of Alberta Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1S6
- McGill Cancer Centre at McGill University
-
Montreal, Quebec, Canada, H2L 4MI
- Centre Hospitalier de l'Universite de Montreal
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85013
- Foundation for Cancer Research and Education
-
-
California
-
San Francisco, California, Verenigde Staten, 94115
- UCSF Comprehensive Cancer Center
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32610-0385
- University of Florida Shands Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109-0010
- University of Michigan Comprehensive Cancer Center
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64131
- CCOP - Kansas City
-
-
New Jersey
-
Long Branch, New Jersey, Verenigde Staten, 07740-6395
- Monmouth Medical Center
-
Toms River, New Jersey, Verenigde Staten, 08755
- Community Regional Cancer Center at Community Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107-5541
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030-4009
- M.D. Anderson Cancer Center at University of Texas
-
-
Utah
-
Saint George, Utah, Verenigde Staten, 84770
- Dixie Regional Medical Center
-
Salt Lake City, Utah, Verenigde Staten, 84143
- LDS Hospital
-
-
Vermont
-
Rutland, Vermont, Verenigde Staten, 05701
- Community Cancer Center at Rutland Regional Medical Center
-
-
Wisconsin
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- CCOP - Marshfield Clinic Research Foundation
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Medical College of Wisconsin Cancer Center
-
Racine, Wisconsin, Verenigde Staten, 53405
- All Saints Cancer Center at All Saints Healthcare
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS:
Histologically proven stage II or III (T1-T2, N0-N1) squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or palate)
- Lymph nodes in both sides of neck at risk of metastatic disease and require radiotherapy
- Patients upstaged by imaging to N2 are eligible
Measurable or evaluable disease
- Greater than 1 cm in one dimension or with necrotic regions if by CT or MRI scan
- Surgery of the primary tumor or lymph nodes limited to incisional or excisional biopsies
- No distant metastases
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- Zubrod 0-1
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- No active untreated infection
- No other malignancy within the past 5 years except nonmelanoma skin cancer or a carcinoma not of head or neck origin
- No concurrent major medical or psychiatric illness that would preclude study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- More than 3 months since prior chemotherapy
- No concurrent chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior head or neck radiotherapy
Surgery:
- See Disease Characteristics
Other:
- No other concurrent treatment for head and neck cancer
- No prophylactic amifostine or pilocarpine
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
---|
Acute salivary gland toxicity
|
Locoregional control
|
Whole mouth saliva output relative to pre-radiotherapy measurements
|
Acute mucositis and other acute and late toxicities
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie stoel: Avraham Eisbruch, MD, University of Michigan Rogel Cancer Center
Publicaties en nuttige links
Algemene publicaties
- Ploquin N, Lau H, Dunscombe P. Intensity modulated and three-dimensional conformal radiation therapy plans for oropharyngeal cancer: a comparison of their sensitivity to set-up errors and uncertainties. Curr Oncol. 2006 Apr;13(2):61-6.
- Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, Sanguineti G, Jones CU, Bosch WR, Ang KK. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1333-8. doi: 10.1016/j.ijrobp.2009.04.011. Epub 2009 Jun 18.
- Eisbruch A, Harris J, Garden A, et al.: Phase II multi-institutional study of IMRT for oropharyngeal cancer (RTOG 00-22): early results. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-79, S46-7, 2006.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- RTOG-0022
- CDR0000068231
- RTOG-H-0022
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op bestralingstherapie
-
Varian, a Siemens Healthineers CompanyWashington University School of MedicineWervingSpierinvasieve blaas urotheelcarcinoomVerenigde Staten
-
Hokkaido University HospitalVoltooid
-
HekabioVoltooidBorstkanker | Hoofd-halskankerJapan
-
Varian, a Siemens Healthineers CompanyWashington University School of MedicineWervingAlvleesklierkankerVerenigde Staten
-
Spectrum Pharmaceuticals, IncVoltooidBorstkanker | MetastasenVerenigde Staten, Canada, Frankrijk, Spanje, Verenigd Koninkrijk, Oostenrijk, Argentinië, Brazilië, Chili, Kroatië, Griekenland, Hongarije, Italië, Litouwen, Peru
-
Spanish Oncology Genito-Urinary GroupRoche Farma, S.A; Dynamic Science S.L.Actief, niet wervend
-
Philogen S.p.A.VoltooidHersenmetastasen van solide tumorenItalië, Verenigd Koninkrijk
-
Hoosier Cancer Research NetworkMerck Sharp & Dohme LLCBeëindigdCarcinoom, niet-gespecificeerde locatieVerenigde Staten
-
University of MiamiIngetrokken
-
National University Hospital, SingaporeOnbekend